Analysts think ALNY stock price could increase by 25%
Apr 04, 2025, 11:25 AM
-1.10%
What does ALNY do
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
32 analysts think ALNY stock price will increase by 25.43%. The current median analyst target is $328.95 compared to a current stock price of $262.25. The lowest analysts target is $196.95 and the highest analyst target is $525.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
